PTHS Stock Summary and Trading Ideas (Pelthos Therapeutics | AMEX:PTHS)

Pelthos Therapeutics Inc is a biopharmaceutical company committed to commercializing safe and efficacious therapeutic products to help patients with unmet treatment burdens. The Company currently has three U.S. Food and Drug Administration (FDA) approved products in its commercial portfolio, in various stages of commercialization, including ZELSUVMITM, XEPI, and XEGLYZE. The company operates in two reporting segments: the sale, promotion, and commercialization of approved commercial products, the Commercial Operations segment, and research and development activities related to developing a novel and proprietary class of NaV blockers that target the body's peripheral nervous system; and supportive activities to expand the NITRICIL nitric oxide-based technology.

Pelthos Therapeutics trades on the AMEX stock market under the symbol PTHS.

As of June 23, 2026, PTHS stock price climbed to $29.50 with 22,173 million shares trading.

PTHS has a beta of 2.01, meaning it tends to be more sensitive to market movements. PTHS has a correlation of 0.10 to the broad based SPY ETF.

PTHS has a market cap of $102.53 million. This is considered a Micro Cap stock.

Last quarter Pelthos Therapeutics reported $11 million in Revenue and -$3.09 earnings per share. This beat revenue expectation by $607,832 and exceeded earnings estimates by $.57.

The top ETF exchange traded funds that PTHS belongs to (by Net Assets): VTI, VXF.

PTHS support price is $27.67 and resistance is $30.89 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PTHS shares will trade within this expected range on the day.